Florence Dalenc

15.9k total citations · 3 hit papers
209 papers, 4.5k citations indexed

About

Florence Dalenc is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Florence Dalenc has authored 209 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Oncology, 89 papers in Pulmonary and Respiratory Medicine and 86 papers in Cancer Research. Recurrent topics in Florence Dalenc's work include Cancer Treatment and Pharmacology (71 papers), Advanced Breast Cancer Therapies (64 papers) and Breast Cancer Treatment Studies (57 papers). Florence Dalenc is often cited by papers focused on Cancer Treatment and Pharmacology (71 papers), Advanced Breast Cancer Therapies (64 papers) and Breast Cancer Treatment Studies (57 papers). Florence Dalenc collaborates with scholars based in France, United States and Belgium. Florence Dalenc's co-authors include Mario Campone, Henri Roché, Marc Poirot, Thomas Bachelot, Anthony Gonçalvès, Sandrine Silvente‐Poirot, Jean-Marc Ferrero, Véronique Dièras, Hope S. Rugo and Marta Jimenez and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Florence Dalenc

195 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

2012 522 citations Thomas Bachelot, Gilles Romieu et al. profile →
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

2023 210 citations Hope S. Rugo, Aditya Bardia et al. profile →
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

2022 176 citations Hope S. Rugo, Aditya Bardia et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Florence Dalenc France	33	2.6k	1.6k	1.3k	1.3k	428	209	4.5k
Erica L. Mayer United States	31	2.6k 1.0×	997 0.6×	1.2k 0.9×	1.4k 1.0×	297 0.7×	144	4.7k
William Jacot France	34	2.7k 1.0×	1.4k 0.9×	1.2k 0.9×	1.1k 0.8×	396 0.9×	224	4.2k
Yeon Hee Park South Korea	34	2.5k 0.9×	1.3k 0.8×	1.5k 1.2×	1.1k 0.9×	486 1.1×	196	4.1k
Otto Metzger United States	30	3.2k 1.2×	1.4k 0.9×	1.7k 1.3×	1.4k 1.0×	540 1.3×	117	4.8k
Daniele Generali Italy	42	3.1k 1.2×	1.7k 1.1×	2.1k 1.6×	2.5k 1.9×	490 1.1×	232	6.2k
Mario Giuliano Italy	34	2.4k 0.9×	1.2k 0.8×	1.4k 1.1×	1.0k 0.8×	328 0.8×	109	3.8k
Toshinari Yamashita Japan	24	1.9k 0.7×	1.6k 1.0×	1.1k 0.8×	1.3k 1.0×	211 0.5×	135	3.7k
Przemyslaw Twardowski United States	29	2.2k 0.8×	2.4k 1.5×	1.2k 0.9×	1.6k 1.2×	464 1.1×	113	4.3k
Nina J. Karlin United States	15	2.2k 0.8×	969 0.6×	1.1k 0.8×	1.4k 1.1×	555 1.3×	47	4.1k
Paul Frankel United States	34	1.9k 0.7×	967 0.6×	658 0.5×	1.8k 1.3×	404 0.9×	214	4.1k

Countries citing papers authored by Florence Dalenc

Since Specialization

Citations

This map shows the geographic impact of Florence Dalenc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florence Dalenc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florence Dalenc more than expected).

Fields of papers citing papers by Florence Dalenc

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florence Dalenc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florence Dalenc. The network helps show where Florence Dalenc may publish in the future.

Co-authorship network of co-authors of Florence Dalenc

This figure shows the co-authorship network connecting the top 25 collaborators of Florence Dalenc. A scholar is included among the top collaborators of Florence Dalenc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florence Dalenc. Florence Dalenc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bidard, François‐Clément, Frédérique Berger, Mónica Arnedos, et al.. (2024). Clinical utility of ctDNA as a tool to detect triple-negative breast cancer relapses: The CUPCAKE trial.. Journal of Clinical Oncology. 42(16_suppl). TPS1139–TPS1139. 1 indexed citations

Vanacker, Hélène, Isabelle Treilleux, Camille Schiffler, et al.. (2024). p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. British Journal of Cancer. 130(4). 613–619.

Lamy, Sébastien, et al.. (2023). Access to information and oncofertility consultation for young women with breast cancer: a population-based study. Scientific Reports. 13(1). 3313–3313. 7 indexed citations

Licaj, Idlir, Elodie Coquan, Tienhan Sandrine Dabakuyo‐Yonli, et al.. (2023). Baseline quality of life and chemotherapy toxicities in patients with early breast cancer. Cancer. 129(7). 1085–1095. 4 indexed citations

Bidard, François‐Clément, Nicolas Kiavué, William Jacot, et al.. (2023). Overall Survival With Circulating Tumor Cell Count–Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial. Journal of Clinical Oncology. 42(4). 383–389. 28 indexed citations

Buscato, Mélissa, et al.. (2023). The beneficial effects of tamoxifen on arteries: A key player for cardiovascular health of breast cancer patient. Biochemical Pharmacology. 214. 115677–115677. 5 indexed citations

Wildiers, Hans, Anne Armstrong, Eveline Cuypere, et al.. (2023). Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial. Clinical Cancer Research. 30(3). 532–541. 12 indexed citations

Sabatier, Renaud, Cécile Vicier, Séverine Garnier, et al.. (2022). Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. Molecular Oncology. 16(10). 2057–2070. 5 indexed citations

Rugo, Hope S., Aditya Bardia, Frederik Marmé, et al.. (2022). Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. Journal of Clinical Oncology. 40(29). 3365–3376. 176 indexed citations breakdown →

10.

Aziza, R., C. Chira, Eva Jouve, et al.. (2021). Diagnosis, biology and epidemiology of oligometastatic breast cancer. The Breast. 59. 144–156. 6 indexed citations

11.

Marcheteau, Elie, Thomas Farge, Michaël Pérès, et al.. (2021). Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer. Cancers. 13(16). 4059–4059. 11 indexed citations

12.

Franchet, Camille, Jean‐Sèbastien Hoffmann, & Florence Dalenc. (2021). Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer. Cancers. 13(16). 4132–4132. 6 indexed citations

13.

Pons‐Tostivint, Elvire, et al.. (2020). Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?. Critical Reviews in Oncology/Hematology. 157. 103146–103146. 9 indexed citations

14.

Jacot, William, Florence Dalenc, Evelyne Lopez‐Crapez, et al.. (2019). PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. Breast Cancer Research and Treatment. 177(3). 659–667. 18 indexed citations

15.

Gui, Philippe, Florence Dalenc, Camille Franchet, et al.. (2018). The Protease-Dependent Mesenchymal Migration of Tumor-Associated Macrophages as a Target in Cancer Immunotherapy. Cancer Immunology Research. 6(11). 1337–1351. 28 indexed citations

16.

Kaufman, Peter A., Gilles Freyer, Margaret Kemeny, et al.. (2015). A phase 1b study of Trebananib plus Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in patients with HER2+ locally recurrent or metastatic breast cancer. Open Repository and Bibliography (University of Liège). 1 indexed citations

17.

André, Fabrice, Thomas Bachelot, Mario Campone, et al.. (2013). Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer. Clinical Cancer Research. 19(13). 3693–3702. 251 indexed citations

18.

Berlière, Martine, François P. Duhoux, Florence Dalenc, et al.. (2013). Correction: Tamoxifen and Ovarian Function. PLoS ONE. 8(10). 10 indexed citations

19.

Dalenc, Florence, Sophie Doisneau-Sixou, Ben Allal, et al.. (2010). Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis. Clinical Cancer Research. 16(4). 1264–1271. 21 indexed citations

20.

Lacroix‐Triki, Magali, Sandra Pierredon, Lise Gratadou, et al.. (2009). Widespread Estrogen-Dependent Repression of microRNAs Involved in Breast Tumor Cell Growth. Cancer Research. 69(21). 8332–8340. 208 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact